CliffBio
biologic

Bavencio

avelumab

Loss of exclusivityMarch 2029projected — 12-year biologic exclusivity estimate
CompanyEMD Serono →View the full company profile on CliffBio

Drug detail

Brand nameBavencio
Active ingredientavelumab
Strength200MG/10ML (20MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2017
Marketing statusRx

More from EMD Serono

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Bavencio patent cliff — loss of exclusivity March 2029 | CliffBio